SCHEMBL665000

SCHEMBL665000

Cc1cccc2sc(NC(=O)c3ccc(S(=O)(=O)N4CCCc5ccccc54)cc3)nc12

nearest known ligand 0.81

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.81
MAPT P10636 13/20 0.78
LMNA P02545 7/20 0.78
POLB P06746 4/20 0.78
KDM4E B2RXH2 6/20 0.76
SMN1; SMN2 Q16637 5/20 0.76
ALDH1A1 P00352 4/20 0.76
HPGD P15428 3/20 0.76
RECQL P46063 1/20 0.76
MEN1 O00255 3/20 0.72
KMT2A Q03164 3/20 0.72
RAB9A P51151 3/20 0.64
HTT P42858 2/20 0.64
NPC1 O15118 1/20 0.64
AR P10275 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.59
NR3C1 P04150 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18020440 0.91 TP53 (0.67) TP53MAPTLMNAPOLBKDM4E
SCHEMBL665069 0.87 MAPT (0.81) TP53MAPTLMNAPOLBKDM4E
SCHEMBL21376551 0.84 MAPT (0.58) TP53MAPTLMNAPOLBKDM4E
SCHEMBL662501 0.84 MAPT (1.00) TP53MAPTLMNAPOLBKDM4E
SCHEMBL29978060 0.84 MAPT (1.00) TP53MAPTLMNAPOLBKDM4E
SCHEMBL21376339 0.82 MAPT (0.56) TP53MAPTLMNAPOLBKDM4E
SCHEMBL21909790 0.82 MAPT (0.57) TP53MAPTLMNAPOLBKDM4E
SCHEMBL665159 0.82 LMNA (0.68) TP53MAPTLMNAPOLBKDM4E
SCHEMBL21376494 0.81 MAPT (0.68) TP53MAPTLMNAPOLBKDM4E
SCHEMBL664475 0.80 MAPT (0.81) TP53MAPTLMNAPOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834446-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
US-11834446-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
US-11834446-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
US-20230110928-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC. 2023-04-13 US disclosed
US-11512081-B2 Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2022-11-29 US disclosed
US-20210188835-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC. 2021-06-24 US disclosed
US-20210188835-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC. 2021-06-24 US disclosed
US-10975067-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2021-04-13 US disclosed
US-10975067-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2021-04-13 US disclosed
EP-3626240-A1 PROCESS OF PREPARATION OF A N-ARYL BENZYL SULFONAMIDE SUBSTITUTED WITH AN AMIDO GROUP StemSynergy Therapeutics, Inc. (US) 2020-03-25 EP disclosed
US-9416101-B2 Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2016-08-16 US disclosed
US-20150051177-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC. 2015-02-19 US disclosed
US-20150051177-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC. 2015-02-19 US disclosed
US-8901306-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2014-12-02 US disclosed
US-8901306-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2014-12-02 US disclosed
US-8901306-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2014-12-02 US disclosed
US-20120046250-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC (US) 2012-02-23 US disclosed
US-20120046250-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC (US) 2012-02-23 US disclosed
US-20120046250-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC (US) 2012-02-23 US disclosed
WO-2010101964-A2 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC (US) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834446-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell WNT3A, WNT1, WNT3 TP53 24/4885MAPT 3825/4885LMNA 1384/4885
US-10975067-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell WNT3A, WNT1, WNT3 TP53 24/4885MAPT 3825/4885LMNA 1384/4885
US-20230110928-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL WNT3A, WNT1, WNT3 TP53 24/4885MAPT 3825/4885LMNA 1384/4885
US-20150051177-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL WNT3A, WNT1, WNT3 TP53 24/4885MAPT 3825/4885LMNA 1384/4885
US-11512081-B2 Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell WNT3A, WNT1, WNT3 TP53 24/4885MAPT 3825/4885LMNA 1384/4885
US-20120046250-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL WNT3A, WNT1, WNT3 TP53 24/4885MAPT 3825/4885LMNA 1384/4885
US-20210188835-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL WNT3A, WNT1, WNT3 TP53 24/4885MAPT 3825/4885LMNA 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.